Abstract

BackgroundHerbal medicines have been used in cancer treatment, with many exhibiting favorable side effect and toxicity profiles compared with conventional chemotherapeutic agents. SH003 is a novel extract from Astragalus membranaceus, Angelica gigas, and Trichosanthes Kirilowii Maximowicz combined at a 1:1:1 ratio that impairs the growth of breast cancer cells. This study investigates anti-cancer effects of SH003 in prostate cancer cells.MethodsSH003 extract in 30% ethanol was used to treat the prostate cancer cell lines DU145, LNCaP, and PC-3. Cell viability was determined by MTT and BrdU incorporation assays. Next, apoptotic cell death was determined by Annexin V and 7-AAD double staining methods. Western blotting was conducted to measure protein expression levels of components of cell death and signaling pathways. Intracellular reactive oxygen species (ROS) levels were measured using H2DCF-DA. Plasmid-mediated ERK2 overexpression in DU145 cells was used to examine the effect of rescuing ERK2 function. Results were analyzed using the Student’s t-test and P-values < 0.05 were considered to indicate statistically-significant differences.ResultsOur data demonstrate that SH003 induced apoptosis in DU145 prostate cancer cells by inhibiting ERK signaling. SH003 induced apoptosis of prostate cancer cells in dose-dependent manner, which was independent of androgen dependency. SH003 also increased intracellular ROS levels but this is not associated with its pro-apoptotic effects. SH003 inhibited phosphorylation of Ras/Raf1/MEK/ERK/p90RSK in androgen-independent DU145 cells, but not androgen-dependent LNCaP and PC-3 cells. Moreover, ERK2 overexpression rescued SH003-induced apoptosis in DU145 cells.ConclusionsSH003 induces apoptotic cell death of DU145 prostate cancer cells by inhibiting ERK2-mediated signaling.Electronic supplementary materialThe online version of this article (doi:10.1186/s12906-016-1490-5) contains supplementary material, which is available to authorized users.

Highlights

  • Herbal medicines have been used in cancer treatment, with many exhibiting favorable side effect and toxicity profiles compared with conventional chemotherapeutic agents

  • SH003 induces apoptosis in DU145 prostate cancer cells We first investigated the effects of SH003 on the viability of DU145 prostate cancer cells using MTT assays

  • Intracellular reactive oxygen species (ROS) generation is not involved in SH003-mediated apoptosis ROS induces apoptotic cell death [27,28,29], so we examined whether treatment with SH003 increased intracellular ROS levels

Read more

Summary

Introduction

Herbal medicines have been used in cancer treatment, with many exhibiting favorable side effect and toxicity profiles compared with conventional chemotherapeutic agents. SH003 is a novel extract from Astragalus membranaceus, Angelica gigas, and Trichosanthes Kirilowii Maximowicz combined at a 1:1:1 ratio that impairs the growth of breast cancer cells. This study investigates anti-cancer effects of SH003 in prostate cancer cells. Prostate cancer is the second-most common cancer occurring in men in the United States [1]. The development of new drugs should aid prostate cancer patients. Almost all prostate cancers develop from glandular cells, and are classified as adenocarcinomas. Prostate cancer cells are classified into androgendependent and-independent groups. Androgenindependent cells proliferate rapidly and their presence is associated with a poor prognosis [5, 6]. The development of novel therapeutic strategies to treat androgen-unresponsive prostate cancer cells is required

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call